Cargando…

SAT-480 Clinical Cases TSH Secreting Adenomas

Introduction:TSH-secreting pituitary tumors represent about 2% of all pituitary adenomas and cause central hyperthyroidism. These tumors are characterized by high levels of free thyroid hormones in the presence of nonsuppressed serum TSH concentrations.Clinical cases: 1:A 52-year womanwith menstrual...

Descripción completa

Detalles Bibliográficos
Autores principales: Calasans, Camila, Schapira Wajman, Delane, Frigini Scardua, Deborah, Barbosa de Oliveira, Mariana, Russoni, Ana Cláudia, da Cunha Scalco Tirapeli, Renata, Scalissi, Nilza, Lima, Jose, Bueno, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552171/
http://dx.doi.org/10.1210/js.2019-SAT-480
_version_ 1783424540947251200
author Calasans, Camila
Schapira Wajman, Delane
Frigini Scardua, Deborah
Barbosa de Oliveira, Mariana
Russoni, Ana Cláudia
da Cunha Scalco Tirapeli, Renata
Scalissi, Nilza
Lima, Jose
Bueno, Cristina
author_facet Calasans, Camila
Schapira Wajman, Delane
Frigini Scardua, Deborah
Barbosa de Oliveira, Mariana
Russoni, Ana Cláudia
da Cunha Scalco Tirapeli, Renata
Scalissi, Nilza
Lima, Jose
Bueno, Cristina
author_sort Calasans, Camila
collection PubMed
description Introduction:TSH-secreting pituitary tumors represent about 2% of all pituitary adenomas and cause central hyperthyroidism. These tumors are characterized by high levels of free thyroid hormones in the presence of nonsuppressed serum TSH concentrations.Clinical cases: 1:A 52-year womanwith menstrual irregularity and hyperprolactinemia (127ng/mL). The pituitary´s MR showed a lesion (2.0 x1.8 x1.8cm). The diagnosis of TSHoma was made later when TSH achieved 4,78µU/mL (0.27-4.2), FT4 1.9ng/dL(0.93-1.7) and TRH stimulation test compatible. Treated with Ocreotide LAR (OCT LAR) and cabergoline, but the tumor became invasive. The surgery was indicated but the patient refused. 2:A 56-year womanwith weight loss, insomnia and hair loss. TSH 5.66µU/mL(0.5-5.3), FT4 2.4ng/mL(0.7-1.6), SHBG elevated, negativeantibodies andα-GSU in the normal range. The TRH stimulation test was compatible with TSHoma. The MR presented a tumor with 0.9x0.8x0.7cm. Treated with OCT LAR: good control of hyperthyroidism symptoms. 3: A 55-year man with headachesand visual field loss. TSH 2.47µU/mL(0.5-5.3), FT4 2.3ng/mL(0.7-1.6) and negative antibodies. The pituitary MR presented a tumor with 1.1x1.0x1.0cm and compression of the optic chiasm. The diagnosis was confirmed with the TRH stimulation and high level of α-GSU. The patient had an arrhythmia and the surgery was cancelled. He has been treated successfully with OCT LAR. 4: A 45-year-old asymptomatic woman with routine tests: TSH 5.11 μUI/mL(0.27-5.0), FT4 1.97ng/dL(0.75-1.10) and negative antibodies. The diagnosis was confirmed by α-GSU, TRH stimulation andpituitary lesion with 2.1x1.9x1.8cm. She has been treated with OCTand presented normalization of hormones, α-GSU and tumorreduction. 5:A 62-year-old woman with tremors, TSH 13.9 µUI/mL (0.45-4,5), FT4 2.2 ng/mL (0.6-1.3) and positive anti-TPO. The α-GSU was normal for postmenopausal woman, but had a high α-GSU/TSH molar ratio. The pituitary´s MR showed a lesion with 5 mm. The treatment with OCT LAR was indicated. 6:A 59-year-old woman withhyperthyroidism clinic and liver cirrhosis. TSH 6.29µUI/L (0.27-4.2), FT4 3.2ng/dL(0.93-1.7),α-GSU 2251ng/L (340-4000) and a 0.9 cm pituitary lesion. There was no tumor control with OCT LAR. Transesphenoidal surgery couldn'tbe considered because of coagulation disorders. Antithyroid drugs was contraindicated due to its hepatotoxicity. Then weperformed a radiosurgery but the patient lead to death after intestinalhemorrhage. 7:A 51-year-old man complaining of palpitations, irritability and tiredness. Laboratory tests showed an increase in FT4L: 2.3ng/dL (0.9-1.7) with inappropriately normal TSH: 1.77 μUI/L (0.27-4.2) and presence of pituitary microadenoma.Conclusion: In the presence of inappropriate normal or increased TSH levels and high FT4 levels the TSH- secreting pituitary adenoma should be considered even though is a rare disease.
format Online
Article
Text
id pubmed-6552171
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65521712019-06-13 SAT-480 Clinical Cases TSH Secreting Adenomas Calasans, Camila Schapira Wajman, Delane Frigini Scardua, Deborah Barbosa de Oliveira, Mariana Russoni, Ana Cláudia da Cunha Scalco Tirapeli, Renata Scalissi, Nilza Lima, Jose Bueno, Cristina J Endocr Soc Neuroendocrinology and Pituitary Introduction:TSH-secreting pituitary tumors represent about 2% of all pituitary adenomas and cause central hyperthyroidism. These tumors are characterized by high levels of free thyroid hormones in the presence of nonsuppressed serum TSH concentrations.Clinical cases: 1:A 52-year womanwith menstrual irregularity and hyperprolactinemia (127ng/mL). The pituitary´s MR showed a lesion (2.0 x1.8 x1.8cm). The diagnosis of TSHoma was made later when TSH achieved 4,78µU/mL (0.27-4.2), FT4 1.9ng/dL(0.93-1.7) and TRH stimulation test compatible. Treated with Ocreotide LAR (OCT LAR) and cabergoline, but the tumor became invasive. The surgery was indicated but the patient refused. 2:A 56-year womanwith weight loss, insomnia and hair loss. TSH 5.66µU/mL(0.5-5.3), FT4 2.4ng/mL(0.7-1.6), SHBG elevated, negativeantibodies andα-GSU in the normal range. The TRH stimulation test was compatible with TSHoma. The MR presented a tumor with 0.9x0.8x0.7cm. Treated with OCT LAR: good control of hyperthyroidism symptoms. 3: A 55-year man with headachesand visual field loss. TSH 2.47µU/mL(0.5-5.3), FT4 2.3ng/mL(0.7-1.6) and negative antibodies. The pituitary MR presented a tumor with 1.1x1.0x1.0cm and compression of the optic chiasm. The diagnosis was confirmed with the TRH stimulation and high level of α-GSU. The patient had an arrhythmia and the surgery was cancelled. He has been treated successfully with OCT LAR. 4: A 45-year-old asymptomatic woman with routine tests: TSH 5.11 μUI/mL(0.27-5.0), FT4 1.97ng/dL(0.75-1.10) and negative antibodies. The diagnosis was confirmed by α-GSU, TRH stimulation andpituitary lesion with 2.1x1.9x1.8cm. She has been treated with OCTand presented normalization of hormones, α-GSU and tumorreduction. 5:A 62-year-old woman with tremors, TSH 13.9 µUI/mL (0.45-4,5), FT4 2.2 ng/mL (0.6-1.3) and positive anti-TPO. The α-GSU was normal for postmenopausal woman, but had a high α-GSU/TSH molar ratio. The pituitary´s MR showed a lesion with 5 mm. The treatment with OCT LAR was indicated. 6:A 59-year-old woman withhyperthyroidism clinic and liver cirrhosis. TSH 6.29µUI/L (0.27-4.2), FT4 3.2ng/dL(0.93-1.7),α-GSU 2251ng/L (340-4000) and a 0.9 cm pituitary lesion. There was no tumor control with OCT LAR. Transesphenoidal surgery couldn'tbe considered because of coagulation disorders. Antithyroid drugs was contraindicated due to its hepatotoxicity. Then weperformed a radiosurgery but the patient lead to death after intestinalhemorrhage. 7:A 51-year-old man complaining of palpitations, irritability and tiredness. Laboratory tests showed an increase in FT4L: 2.3ng/dL (0.9-1.7) with inappropriately normal TSH: 1.77 μUI/L (0.27-4.2) and presence of pituitary microadenoma.Conclusion: In the presence of inappropriate normal or increased TSH levels and high FT4 levels the TSH- secreting pituitary adenoma should be considered even though is a rare disease. Endocrine Society 2019-04-30 /pmc/articles/PMC6552171/ http://dx.doi.org/10.1210/js.2019-SAT-480 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Neuroendocrinology and Pituitary
Calasans, Camila
Schapira Wajman, Delane
Frigini Scardua, Deborah
Barbosa de Oliveira, Mariana
Russoni, Ana Cláudia
da Cunha Scalco Tirapeli, Renata
Scalissi, Nilza
Lima, Jose
Bueno, Cristina
SAT-480 Clinical Cases TSH Secreting Adenomas
title SAT-480 Clinical Cases TSH Secreting Adenomas
title_full SAT-480 Clinical Cases TSH Secreting Adenomas
title_fullStr SAT-480 Clinical Cases TSH Secreting Adenomas
title_full_unstemmed SAT-480 Clinical Cases TSH Secreting Adenomas
title_short SAT-480 Clinical Cases TSH Secreting Adenomas
title_sort sat-480 clinical cases tsh secreting adenomas
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552171/
http://dx.doi.org/10.1210/js.2019-SAT-480
work_keys_str_mv AT calasanscamila sat480clinicalcasestshsecretingadenomas
AT schapirawajmandelane sat480clinicalcasestshsecretingadenomas
AT friginiscarduadeborah sat480clinicalcasestshsecretingadenomas
AT barbosadeoliveiramariana sat480clinicalcasestshsecretingadenomas
AT russonianaclaudia sat480clinicalcasestshsecretingadenomas
AT dacunhascalcotirapelirenata sat480clinicalcasestshsecretingadenomas
AT scalissinilza sat480clinicalcasestshsecretingadenomas
AT limajose sat480clinicalcasestshsecretingadenomas
AT buenocristina sat480clinicalcasestshsecretingadenomas